Sectors
Foley & Lardner partner LLP Nathan Beaver shared insight on the U.S. Food and Drug Administration’s oversight of pharmaceutical compounders in the Reuters’ article, “U.S. Could Take Action Including Fines Against Hims After Brief Wegovy Copy Launch.”
Following the FDA’s referral of telehealth company Hims to the U.S. Department of Justice for potential legal violations in the wake of Hims’ launch of a compounded oral GLP-1, Beaver said, “As a next enforcement step, the FDA could inspect Hims’ records to evaluate whether their prescriptions are properly documented, alone or in coordination with state regulators that license compounding pharmacies.”
